ReviewCureus2024
Impact of Sacubitril/Valsartan in Improving Home Time for Patients With Heart Failure.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Home time, defined as time spent by the patient alive and out of any healthcare institution, is an important patient-centric outcome for patients with cardiovascular disease. Home time is recognized as a crucial measure of recovery post cardiovascular events but has not been extensively studied in heart failure (HF) patients, especially in India. HF in India is rapidly growing at an epidemic scale and hence the focus on improving home time in HF patients highlights the need for precise, patient-centered care strategies. Current literature lacks detailed descriptions of hospital-level patterns and predictors of home time in contemporary HF populations, which hinders tailored approaches to optimize outcomes like functional status and health-related quality of life along with reduced hospitalization and mortality risks. Literature is abundant with clinical evidence on the benefits of guideline-directed medical therapy (GDMT), especially angiotensin receptor neprilysin inhibitor (ARNI) therapy, in HF management. All major guidelines highly recommend its initiation for reducing morbidity and mortality in patients with chronic symptomatic HF with reduced ejection fraction. Studies indicate that sacubitril/valsartan, the first in class of ARNI, improves the quality of life and functional outcomes, along with reduced HF-related hospitalizations and cardiovascular deaths. Its unique mechanism of action, combining neprilysin inhibition and angiotensin receptor blockade, targets multiple pathways of HF pathophysiology, leading to improved cardiac function and remodeling. These benefits are pivotal in supporting patients' ability to maintain an active lifestyle outside of healthcare settings. Despite its demonstrated benefits, sacubitril/valsartan is underutilized. Integrating sacubitril/valsartan more optimally into clinical practice could significantly alleviate the overall burden of HF by addressing key determinants of home time and improving patient outcomes post discharge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.